Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Digital dreams and realities clash pharma and biotech in 2023

By Brian Buntz | November 16, 2023

In Laboratory Over the Shoulder View of Scientist in Protective Clothes Doing Research on a Personal Computer. Modern Manufactory Producing Semiconductors and Pharmaceutical Items.

[Adobe Stock]

The tale of digital pharma and biotech in 2023 is one of two realities. In one corner, you have AI and digital-focused startups and sometimes executives at Big Pharma companies with grand AI ambitions proclaiming the power of the technology. But on the other side of the pharma-AI coin is a more cautious crowd. Here, industry veterans and pragmatic managers wrestle with the realities of integrating AI into the tightly regulated and often legacy infrastructure that has guided drug development for decades.

Ambitious plans versus on-the-ground realities

It is true that the vast majority of pharma and biotech companies are working on crafting a strategy for AI tools. Only 1% of the participants in CRB’s Horizons Life Sciences 2023 report said they did not have such a strategy. Three-quarters, 76%, said such a strategy would be implemented within the next two years while 21% said they planned on doing so in the next three to five years. (The survey, which probed the state of digital pharma and biotech in 2023, included responses from over 500 leaders from various-sized companies across North America and Europe.)

Peter Walters

Peter Walters

The most popular areas for AI investments were drug discovery and R&D (48%) followed by quality and regulatory (40%) and clinical manufacturing (34%). Rounding out the top five were supply chain and logistics (27%) and engineering (22%).

For all of the talk about Pharma 4.0 (an ISPE trademark), which refers to the integration of advanced digital technologies, such as AI and IoT, in the pharma industry, executing on those ambitions is rarely straightforward. “Sometimes, the cost of fully implementing these initiatives can be a hard pill to swallow,” said Peter Walters, fellow, advanced therapies at CRB. There is also a staffing burden dimension. “You’ve got the implementation of the systems — the coding, the hardware, and then there’s the massive task of changing workflow practices, training staff, and altering how people work,” Walters continued. While the benefits can be considerable for mature digital initiatives, “the initial lift to get there can be substantial,” Walters said. Resource-strapped companies in particular are more likely to postpone ambitious digital plans.

Challenges in implementing AI and digital strategies in pharma

While nearly all companies have some sort of strategy for AI and digital technologies, many struggle to know how to execute it. “They might be implementing small pieces of their digital transformation plans, laying some groundwork, but the bigger leaps, the major steps in that process, are likely being postponed a bit,” Walters said.

The Horizons report also captured notable skepticism, especially in North America, regarding the return on investment for Industry 4.0 initiatives. Common perceived barriers included cybersecurity (cited by 41%), regulatory concerns (33%), lack of data connectivity (29%) and market confusion (28%).

Digital dreams

Bar graph displaying barriers to adopting data and AI projects with percentages for overall, North America, and Europe. The most significant barriers are lack of evidence of ROI and regulatory concerns, followed by cybersecurity risks and lack of data connectivity. Lesser concerns include market confusion and lack of knowledgeable staff. Source: CRB.

Divergent perspectives on the barriers to data and AI implementation, comparing global, North American, and European corporate sentiments. Image courtesy of CRB.

In the positive column for digital strategies, most sites have a budget in the next two years of at least $1 million for data and AI projects, with 20% having a budget of $10–50 million. In addition, Industry 4.0 initiatives are likely to have C-suite backing.

While the financial commitment to digital initiatives highlights their perceived importance, the potential value of the data that these projects yield stands out. “People are beginning to realize that in some instances, the data can actually be more valuable than the products themselves, depending on the context,” Walters said. That doesn’t necessarily mean that data is worth more than novel therapeutics, but “for companies building technological platforms, especially in emerging areas like cell therapy and branching into stem cells, the collection of all your research data becomes immensely powerful,” Walters added. Such data are crucial for building predictive models, for instance, understanding how stem cells differentiate, or assessing their use and success rates at the patient level. “Data can be extremely valuable to the industry and as a company asset, potentially influencing acquisitions by larger pharma or in sales.”

Embracing digital data strategies in pharma and biotech in 2023

In terms of how pharma and biotech companies use data internally, there is significant potential for organizations to grow more sophisticated in, say, identifying critical process parameters and justifying their recipe parameters, the processes they use, and the endpoints in their label claims for drug products. “Historically, all this data has been confined to notebooks, very paper-bound, making it challenging to synthesize it holistically in a way that’s truly helpful,” Walters said. “It’s all been managed by people, and you’re limited by the intelligence and capability of your staff to devise robust solutions.”

But now, with companies adopting more data strategies and moving away from paper to digital, there’s an opportunity to leverage this data more effectively. Drug developers “can look into the data, pull trends from it in a way that’s more comprehensive, leading to more accurate, better, and faster solutions for these kinds of challenges,” Walters said. “This is a shift from the past, where it was just people sifting through notebooks, and a lot of the knowledge was just dormant on the shelf.”


Filed Under: Data science, Drug Discovery and Development, Industry 4.0, machine learning and AI, Uncategorized
Tagged With: 2023 pharma trends, AI in Pharma, Biopharmaceutical R&D, Biotech Industry Trends, CRB, Digital Biotech 2023, Pharma Digital Transformation, Pharmaceutical Technology
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Why Regeneron’s Lynozyfic FDA approval validates its extreme R&D thesis
Parallel Bio’s $21M in Series A will drive aim to trim $2B and 9 years from drug development timelines
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
From 1.5% to 5.9%: Deloitte digs into what’s fueling Big Pharma’s R&D IRR climb
Recce targets A$15.8M to advance anti-infectives into Phase 3 trials
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE